We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Some HER2-Negative Breast Tumors May Respond to HER2-Targeted Treatment.
- Authors
Rochman, Sue
- Abstract
The article reports on the potential of human epidermal growth factor receptor 2 (HER2)-targeted therapy in treament of HER2-negative breast tumors with certain HER2 mutations. It mentions an analysis by X. Ma, an associate professor of medicine at Washington University School of Medicine in St. Louis, Missouri suggesting the potential clinical benefits of the use of neratinib in treatment of HER2-negative breast tumors.
- Subjects
HER2 protein; BREAST tumor treatment; TARGETED drug delivery; GENETIC mutation; WASHINGTON University (Saint Louis, Mo.). School of Medicine
- Publication
JNCI: Journal of the National Cancer Institute, 2016, Vol 108, Issue 9, p2
- ISSN
0027-8874
- Publication type
journal article
- DOI
10.1093/jnci/djw221